RecruitingPriority 3 · Moderate priorityNCT04087629
StrataCTX® as a Steroid Sparing Device
Plain-language summary
This study is studying StrataCTX® gel for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
StrataCTX® gel (DEVICE): Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
- Drugs / treatments
- StrataCTX® gel
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details